rg4733
Adult Malignant Mesenchymoma
National Cancer Institute (NCI)Phase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 26/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Adult Malignant Mesenchymoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gdc-0449 National Cancer Institute (NCI) | Phase 1/2 | CCC |
Same molecule, other indications
rg4733 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →